Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10109)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
SMPD1
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4) [Suppressor]
In total 2 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Target for Ferroptosis | Marker/Suppressor | |||
Responsed Disease | Fibrosarcoma | ICD-11: 2B53 | ||
Responsed Drug | Erastin | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | |||
Cell Process | Cell ferroptosis | |||
Cell autophagy | ||||
In Vitro Model |
HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 |
Calu-1 cells | Lung squamous cell carcinoma | Homo sapiens | CVCL_0608 | |
HeLa cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
Response regulation | Erastin (Era) treatment results in the activation of ASM and generation of ceramide, which are required for the Era-induced reactive oxygen species (ROS) generation and LPO in fibrosarcoma. ASM ( SMPD1)-mediated activation of autophagy plays a critical role in ferroptosis inducers (FINs)-induced glutat hione peroxidase 4 (GPX4) degradation and ferroptosis activation. | |||
Experiment 2 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Target for Ferroptosis | Marker/Suppressor | |||
Responsed Disease | Fibrosarcoma | ICD-11: 2B53 | ||
Responsed Drug | Erastin | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | |||
Cell Process | Cell ferroptosis | |||
Cell autophagy | ||||
In Vitro Model |
HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 |
Calu-1 cells | Lung squamous cell carcinoma | Homo sapiens | CVCL_0608 | |
HeLa cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
Response regulation | Erastin (Era) treatment results in the activation of ASM and generation of ceramide, which are required for the Era-induced reactive oxygen species (ROS) generation and LPO in fibrosarcoma. ASM (SMPD1)-mediated activation of autophagy plays a critical role in ferroptosis inducers (FINs)-induced glutat hione peroxidase 4 (GPX4) degradation and ferroptosis activation. | |||
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [2] | ||||
Responsed Disease | Injury of intra-abdominal organs | ICD-11: NB91 | |||
Responsed Drug | VBIT-12 | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
mPHs (Mouse primary hepatocytes) | ||||
In Vivo Model |
Male C57 BL /6J mice (6-8 weeks; 18-22 g each) were procured from the Experimental Animal Centre of Shanghai SLAC. All mice were fed in laboratory in vivo facilities with ad libitum food and water, within a temperature-/humidity-regulated environment (22 ± 1 ; Rh. = 65 ± 5%), adopting a 12-h circadian cycling process. Mice fasted overnight for 12 h and were randomly divided into different groups.
Click to Show/Hide
|
||||
Response regulation | The relative amounts of CER and CL in the liver tissues of VBIT-12- or UAMC3203-treated APAP-injured mice markedly increased compared to those of APAP-injured mice. Smpd1 was the CER synthesis gene that was most significantly upregulated by UAMC3203 and VBIT-12. In summary, protecting mitochondria via inhibiting VDAC1 oligomerization alleviates ferroptosis in acetaminophen-induced acute liver injury. | ||||
Fibrosarcoma [ICD-11: 2B53]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | Sphingomyelin phosphodiesterase (SMPD1) | Protein coding | ||
Responsed Drug | Erastin | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | |||
Cell Process | Cell ferroptosis | |||
Cell autophagy | ||||
In Vitro Model |
HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 |
Calu-1 cells | Lung squamous cell carcinoma | Homo sapiens | CVCL_0608 | |
HeLa cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
Response regulation | Erastin (Era) treatment results in the activation of ASM and generation of ceramide, which are required for the Era-induced reactive oxygen species (ROS) generation and LPO in fibrosarcoma. ASM ( SMPD1)-mediated activation of autophagy plays a critical role in ferroptosis inducers (FINs)-induced glutat hione peroxidase 4 (GPX4) degradation and ferroptosis activation. | |||
Experiment 2 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | Sphingomyelin phosphodiesterase (SMPD1) | Protein coding | ||
Responsed Drug | Erastin | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | |||
Cell Process | Cell ferroptosis | |||
Cell autophagy | ||||
In Vitro Model |
HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 |
Calu-1 cells | Lung squamous cell carcinoma | Homo sapiens | CVCL_0608 | |
HeLa cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
Response regulation | Erastin (Era) treatment results in the activation of ASM and generation of ceramide, which are required for the Era-induced reactive oxygen species (ROS) generation and LPO in fibrosarcoma. ASM (SMPD1)-mediated activation of autophagy plays a critical role in ferroptosis inducers (FINs)-induced glutat hione peroxidase 4 (GPX4) degradation and ferroptosis activation. | |||
Injury of intra-abdominal organs [ICD-11: NB91]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [2] | ||||
Target Regulator | Sphingomyelin phosphodiesterase (SMPD1) | Protein coding | |||
Responsed Drug | VBIT-12 | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
mPHs (Mouse primary hepatocytes) | ||||
In Vivo Model |
Male C57 BL /6J mice (6-8 weeks; 18-22 g each) were procured from the Experimental Animal Centre of Shanghai SLAC. All mice were fed in laboratory in vivo facilities with ad libitum food and water, within a temperature-/humidity-regulated environment (22 ± 1 ; Rh. = 65 ± 5%), adopting a 12-h circadian cycling process. Mice fasted overnight for 12 h and were randomly divided into different groups.
Click to Show/Hide
|
||||
Response regulation | The relative amounts of CER and CL in the liver tissues of VBIT-12- or UAMC3203-treated APAP-injured mice markedly increased compared to those of APAP-injured mice. Smpd1 was the CER synthesis gene that was most significantly upregulated by UAMC3203 and VBIT-12. In summary, protecting mitochondria via inhibiting VDAC1 oligomerization alleviates ferroptosis in acetaminophen-induced acute liver injury. | ||||
Erastin
[Investigative]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | |||
Drug for Ferroptosis | Inducer | |||
Response Target | Phospholipid hydroperoxide glutathione peroxidase (GPX4) | Suppressor | ||
Responsed Disease | Fibrosarcoma | ICD-11: 2B53 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | |||
Cell Process | Cell ferroptosis | |||
Cell autophagy | ||||
In Vitro Model |
HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 |
Calu-1 cells | Lung squamous cell carcinoma | Homo sapiens | CVCL_0608 | |
HeLa cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
Response regulation | Erastin (Era) treatment results in the activation of ASM and generation of ceramide, which are required for the Era-induced reactive oxygen species (ROS) generation and LPO in fibrosarcoma. ASM ( SMPD1)-mediated activation of autophagy plays a critical role in ferroptosis inducers (FINs)-induced glutat hione peroxidase 4 (GPX4) degradation and ferroptosis activation. | |||
Experiment 2 Reporting the Ferroptosis-centered Drug Response | [1] | |||
Drug for Ferroptosis | Inducer | |||
Response Target | Phospholipid hydroperoxide glutathione peroxidase (GPX4) | Suppressor | ||
Responsed Disease | Fibrosarcoma | ICD-11: 2B53 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | |||
Cell Process | Cell ferroptosis | |||
Cell autophagy | ||||
In Vitro Model |
HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 |
Calu-1 cells | Lung squamous cell carcinoma | Homo sapiens | CVCL_0608 | |
HeLa cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
Response regulation | Erastin (Era) treatment results in the activation of ASM and generation of ceramide, which are required for the Era-induced reactive oxygen species (ROS) generation and LPO in fibrosarcoma. ASM (SMPD1)-mediated activation of autophagy plays a critical role in ferroptosis inducers (FINs)-induced glutat hione peroxidase 4 (GPX4) degradation and ferroptosis activation. | |||
VBIT-12
[Investigative]
In total 1 item(s) under this drug | |||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [2] | ||||
Drug for Ferroptosis | Suppressor | ||||
Response Target | Unspecific Target | ||||
Responsed Disease | Injury of intra-abdominal organs | ICD-11: NB91 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
mPHs (Mouse primary hepatocytes) | ||||
In Vivo Model |
Male C57 BL /6J mice (6-8 weeks; 18-22 g each) were procured from the Experimental Animal Centre of Shanghai SLAC. All mice were fed in laboratory in vivo facilities with ad libitum food and water, within a temperature-/humidity-regulated environment (22 ± 1 ; Rh. = 65 ± 5%), adopting a 12-h circadian cycling process. Mice fasted overnight for 12 h and were randomly divided into different groups.
Click to Show/Hide
|
||||
Response regulation | The relative amounts of CER and CL in the liver tissues of VBIT-12- or UAMC3203-treated APAP-injured mice markedly increased compared to those of APAP-injured mice. Smpd1 was the CER synthesis gene that was most significantly upregulated by UAMC3203 and VBIT-12. In summary, protecting mitochondria via inhibiting VDAC1 oligomerization alleviates ferroptosis in acetaminophen-induced acute liver injury. | ||||
References